Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update [Yahoo! Finance]
Elevai Labs, Inc. (ELAB)
Company Research
Source: Yahoo! Finance
Elevai Enfinity™ Clinical Trials Showcase Breakthroughs in Skin Firmness, Tone, and Wrinkle Reduction, Reinforcing Leadership in Aesthetic Innovation. Elevai Biosciences Expands Patent Portfolio with EL-22, a Myostatin-Targeting Treatment for Obesity, Addressing Muscle Preservation in Weight Management NEWPORT BEACH, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, today reported financial results for the second quarter ended September 30, 2024 and provided a business update. Financial Results for the Three and Six Months Ended June 30, 2024 $8 Million Public Offering: Elevai raised $8 million in a successful public offering to capitalize the business and support its strategic growth initiatives. Revenue decreased by 4.9% to $527,478 for the three months ended September 30, 2024 compared to revenue for the three months ended September 30, 2023. Revenue increased by 72.3% to $1,74
Show less
Read more
Impact Snapshot
Event Time:
ELAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ELAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ELAB alerts
High impacting Elevai Labs, Inc. news events
Weekly update
A roundup of the hottest topics
ELAB
News
- Elevai Labs Third Quarter 2024 Earnings: US$0.068 loss per share (vs US$0.078 loss in 3Q 2023) [Yahoo! Finance]Yahoo! Finance
- CORRECTION - Elevai Labs Inc.GlobeNewswire
- Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business UpdateGlobeNewswire
- Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange [Yahoo! Finance]Yahoo! Finance
- Elevai Labs Inc. Announces Update and Extension of Pending Offer to ExchangeGlobeNewswire
ELAB
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form 10-Q
- 11/13/24 - Form 8-K
- ELAB's page on the SEC website